A Phase 1/2 First-in-Human Open-Label Dose Escalation Study of Talquetamab a Humanized GPRC5D x CD3 Bispecific Antibody in Subjects with Relapsed or Refractory Multiple Myeloma

Go Back to All Clinical Trials

A Phase 1/2 First-in-Human Open-Label Dose Escalation Study of Talquetamab a Humanized GPRC5D x CD3 Bispecific Antibody in Subjects with Relapsed or Refractory Multiple Myeloma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Multiple Myeloma
Age: Between 18 Year(s) - 90 Year(s)
Gender: Male or Female

Other Inclusion Criteria:

1) Subjects with measurable multiple myeloma who have progressed on, or could not tolerate, all available established therapies. 2) Subject must have documented evidence of progressive disease based on investigator’s determination of response by the International Myeloma Working Group (IMWG) 2016 criteria on or within 12 months of their last line of therapy.

You may not be eligible for this study if the following are true:

1) Toxicities from previous anticancer therapies should have resolved to baseline levels or to Grade 1 or less except for alopecia or peripheral neuropathy. 2) Known to be seropositive for human immunodeficiency virus or acquired immune deficiency syndrome. 3) Pulmonary compromise requiring supplemental oxygen use to maintain adequate oxygenation.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies